USA Financial Formulas’s DexCom DXCM Stock Holding History

USA Financial Formulas’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,687	Closed	-$985K	–	294
2024 Q2	$985K	Buy	+8,687	New	+$1.1M	0.16%	72
2024 Q1	–	Sell	-101	Closed	-$12.5K	–	338
2023 Q4	$12.5K	Sell	101 -4	-4%	-$409	﹤0.01%	248
2023 Q3	$9.8K	Buy	105 +101	+2,525%	+$11.4K	0.01%	228
2023 Q2	$514	Hold	4	–	–	﹤0.01%	426
2023 Q1	$465	Buy	+4	New	+$448	﹤0.01%	370
2022 Q3	$0	Hold	4	–	–	﹤0.01%	330
2022 Q2	$0	Hold	4	–	–	﹤0.01%	359
2022 Q1	$1K	Buy	+4	New	+$438	﹤0.01%	286
2020 Q4	–	Sell	-25,020	Closed	-$2.58M	–	340
2020 Q3	$2.58M	Sell	25,020 -19,264	-44%	-$2.01M	1.95%	8
2020 Q2	$4.49M	Buy	44,284 +33,576	+314%	+$3M	3.34%	7
2020 Q1	$721K	Buy	10,708 +8,304	+345%	+$517K	0.46%	67
2019 Q4	$131K	Buy	+2,404	New	+$114K	0.05%	155
2019 Q3	–	Sell	-24	Closed	-$1K	–	222
2019 Q2	$1K	Hold	24	–	–	﹤0.01%	116
2019 Q1	$1K	Buy	+24	New	+$843	﹤0.01%	116

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

USA Financial Formulas's DXCM Position: Q3 2024 in Review

USA Financial Formulas sold out of DexCom (DXCM) in Q3 2024, closing a stake of 8,687 shares — an estimated $985K sold.

USA Financial Formulas first reported a position in DXCM in Q1 2019 and held it in 14 quarters. The position peaked at $4.49M in Q2 2020. 890 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

USA Financial Formulas reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
USA Financial Formulas sold 8,687 DexCom shares in Q3 2024, an estimated $985K.
USA Financial Formulas first reported a position in DexCom in Q1 2019 and held it in 14 quarters.
USA Financial Formulas's DexCom position peaked at $4.49M in Q2 2020.
890 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on USA Financial Formulas's 13F filing for Q3 2024, filed 8 Oct 2024.